Regarding the time frame for a Phase 3 progression announcement following the EOP2 meeting, the short answer is I don't know. The company is required to send the FDA Ph2 data and Ph3 plans prior to the meeting for pre-assessment and I'm sure this would help expedite an outcome however it would depend on what feedback, recommendations and subsequent amendments to the Ph3 plan come from that.
As @runaway stated, the meeting will happen regardless of Ph2 result and while a positive EOP2 outcome to progress to Ph3 would no doubt help the SP, one would assume majority of the rerate would have already occurred IF the Ph2 results were positive basis natural assumption Ph3 is a given at that point anyway.
Let "The Hunt For Green October" begin.
Ann: Botanix Investor Presentation, page-87
-
- There are more pages in this discussion • 90 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.5¢ |
Change
-0.005(1.39%) |
Mkt cap ! $642.5M | |||
| Open | High | Low | Value | Volume |
| 36.5¢ | 37.0¢ | 35.0¢ | $1.693M | 4.721M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 40362 | 35.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.0¢ | 50704 | 1 |
View Market Depth
| Last trade - 16.10pm 23/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |